-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>.
With the rapid development of China's economy and society, people's life, work and other pressures have caused the incidence of mental illness to increase year by year
The anti-schizophrenia drugs currently in clinical use can alleviate the positive symptoms, but most anti-schizophrenia drugs have limited or ineffective efficacy in improving negative symptoms and cognitive function
Based on the historical context and pharmacological characteristics of drug development, the current anti-schizophrenia drugs can be divided into three generations
The third-generation anti-schizophrenia drugs-aripiprazole, briprazole and cariprazine, are partial agonists of dopamine D 2 receptors
Designing drugs with structural information as a guide is a popular route for the research and development of chemical small molecule drugs
Researcher Wang Sheng from the Center of Excellence for Molecular Cells and researcher Cheng Jianjun from the iHuman Institute of ShanghaiTech University are the co-corresponding authors of the paper
Article link: https://
Figure a.
Figure b.